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Acute Myocardial Infarction
5-Year Prognostic Value of No-Reflow Phenomenon
After Percutaneous Coronary Intervention in
Patients With Acute Myocardial Infarction
Gjin Ndrepepa, MD,* Klaus Tiroch, MD,* Massimiliano Fusaro, MD,* Dritan Keta, MD,*
Melchior Seyfarth, MD,* Robert A. Byrne, MD,* Jürgen Pache, MD,* Patricia Alger, MD,*
Julinda Mehilli, MD,* Albert Schömig, MD,*† Adnan Kastrati, MD*
Munich, Germany
Objectives The objective of this study was to investigate the impact of no-reflow phenomenon on 5-year mortality among
patients with acute ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coro-
nary intervention (PCI). This impact was also assessed in relation to infarct size.
Background The impact of no-reflow on long-term mortality in patients with STEMI has been insufficiently studied.
Methods This study included 1,406 patients with STEMI treated by primary PCI. No-reflow was diagnosed using angio-
graphic criteria. Infarct size was measured with single-photon emission computed tomography imaging 7 to 14
days after the acute event. The primary outcome was 5-year mortality.
Results The no-reflow phenomenon was diagnosed in 410 patients (29%). Infarct size was 15.0% (6.0% to 29.0%) of the
left ventricle in the no-reflow group versus 8.0% (2.0% to 21.0%) of the left ventricle in the reflow group (p 
0.001). There were 132 deaths during follow-up. Of them, 59 deaths occurred among patients with no-reflow
and 73 deaths occurred among patients with reflow (Kaplan-Meier estimates of 5-year mortality 18.2% and
9.5%, respectively; odds ratio: 2.02; 95% confidence interval: 1.44 to 2.82; p  0.001). The Cox proportional
hazards model adjusting for infarct size among other variables identified the no-reflow phenomenon as an inde-
pendent correlate of 5-year mortality (hazard ratio: 1.66; 95% confidence interval: 1.17 to 2.36; p  0.004).
Conclusions In patients with STEMI treated by primary PCI, no-reflow phenomenon is a strong predictor of 5-year mortality. No-
reflow phenomenon after PCI provides prognostic information that is independent of and beyond that provided by
infarct size. (J Am Coll Cardiol 2010;55:2383–9) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.054a
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no-reflow phenomenon affects a considerable number of
atients with acute ST-segment elevation myocardial infarc-
ion (STEMI) undergoing primary reperfusion therapy (1,2).
ith the ever-increasing use of primary percutaneous coronary
ntervention (PCI), a better recognition of the no-reflow
henomenon and its treatment is increasingly coming into the
potlight and is expected to become the main focus of research
o further improve the efficacy of reperfusion therapy for
atients with STEMI. Studies on the impact of no-reflow on
ortality have reported short-term mortality, used various
ethods with differences in sensitivity to detect the no-reflow,
rom the *Deutsches Herzzentrum and the †1. Medizinische Klinik Rechts der Isar,
echnische Universität, Munich, Germany.y
Manuscript received October 14, 2009; revised manuscript received November 24,
009, accepted December 17, 2009.nd importantly, have included limited numbers of patients
3–7). Few studies with small sample sizes have reported
ong-term prognosis in patients with no-reflow phenomenon
8,9). Experimental and clinical studies have demonstrated that
o-reflow phenomenon is associated with large myocardial
ecrosis (10–12), known to be an important predictor of
ortality (13,14). Although hypotheses have been raised that
o-reflow may offer prognostic information beyond that me-
iated by infarct size (3), no studies have proven these
ypotheses in clinical setting.
The objectives of the current study were, first, to inves-
igate the impact of no-reflow phenomenon on 5-year
ortality in patients with STEMI treated with primary
CI, and second, to explore whether no-reflow phenome-
on offers prognostic information independent of and be-
ond that provided by infarct size.
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Patients. Between January 2002
and December 2007, 1,861 pa-
tients with STEMI presenting
within the first 24 h from the
symptom onset were admitted to
the Deutsches Herzzentrum and
1. Medizinische Klinik Rechts
der Isar in Munich, Germany.
Patients undergoing conservative
therapy (n  112), thrombolysis
(n  35), or coronary artery by-
pass surgery as primary reperfu-
sion strategy (n  18), and pa-
tients with missing scintigraphic
examination (n  173), mechan-
ical failures to open the occluded
coronary arteries (n  31), and
ngiograms of inadequate quality (n  86) were excluded.
hus, the current study included 1,406 patients with
TEMI who underwent primary PCI and had scintigraphic
nfarct size measurement obtained 7 to 14 days after
ntervention. The diagnosis of STEMI was established in
he presence of chest pain lasting 20 min associated with
lectrocardiographic changes (ST-segment elevation 1
m in at least 2 extremity electrocardiographic leads or 2
m in at least 2 contiguous precordial leads or left bundle
Demographic and Clinical Characteristics in PatTable 1 Demographic and Clinical Characte
Characteristic No-Reflow
Age, yrs 65.3 [55.
Women 101 (
Body mass index, kg/m2 26.3 [24.
Diabetes mellitus 85 (
Arterial hypertension 281 (
Current smoker 140 (
Hypercholesterolemia, 240 mg/dl 224 (
Prior myocardial infarction 50 (
Prior coronary artery bypass surgery 22 (
Peak troponin, g/l 4.9 [2.3
Peak creatine kinase-MB, U/l 157.5 [80.
C-reactive protein, mg/l 5.0 [0.0
Glomerular filtration rate, ml/min 80.3 [56.
Infarct location
Anterior 177 (
Inferior 180 (
Lateral 53 (
Systolic blood pressure, mm Hg 130.0 [110
Diastolic blood pressure, mm Hg 70.0 [62.
Killip class
I 270 (
II 97 (
III 20 (
IV 23 (
Time-to-admission interval, h 5.0 [2.5
Abbreviations
and Acronyms
CI  confidence interval
OR  odds ratio
PCI  percutaneous
coronary intervention
SPECT  single-photon
emission computed
tomography
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarction
TMPG  Thrombolysis In
Myocardial Infarction
myocardial perfusion gradeData are median [25th; 75th percentiles] or n (%).ranch block of new onset). The diagnosis was confirmed by
oronary angiography in all patients. Glomerular filtration
ate was calculated using the Cockroft-Gault formula.
everity of heart failure was assessed according to Killip
lassification (15). The study was approved by the institu-
ional ethics committee.
ngiographic analysis and definition of no-reflow.
oronary angiography was performed according to standard
riteria. Offline analysis of digital angiograms was per-
ormed in the core laboratory using an automated edge
etection system (CMS, Medis Medical Imaging Systems,
euen, the Netherlands) by personnel blinded to the clinical
iagnosis. Primary PCI (mostly with stent implantation) and
eriprocedural care were performed according to the standard
riteria. Bare-metal stents were mostly used. Antiplatelet ther-
py consisted of clopidogrel (600 mg as a loading dose followed
y 75 mg/day for at least 4 weeks to 6 months) and aspirin (200
g/day continued indefinitely). Epicardial blood flow in the
nfarct-related artery and myocardial perfusion grade were
raded according to the TIMI (Thrombolysis In Myocardial
nfarction) group definitions (16).
The diagnosis of no-reflow required the following criteria:
) angiographic evidence of reopening of occluded coronary
rtery and successful stent placement with no evidence of
ow-limiting residual stenosis (50%), dissection, spasm, or
pparent thrombus; 2) angiographic documentation of a TIMI
ow grade 2, or a TIMI flow grade 3 with a TIMI
With No-Reflow and Reflows in Patients With No-Reflow and Reflow
10) Reflow (n  996) p Value
] 61.3 [51.6; 71.4] 0.001
244 (25.5) 0.957
] 26.2 [24.1; 28.7] 0.601
190 (19.1) 0.477
702 (70.5) 0.470
454 (45.6) 0.001
517 (51.9) 0.352
121 (12.1) 0.981
25 (2.5) 0.007
3.5 [1.6; 6.6] 0.001
.7] 123.5 [59.0; 252.7] 0.001
3.3 [0.0; 10.0] 0.003
.3] 85.7 [64.5; 107.7] 0.005
0.339
436 (43.8)
400 (40.1)
160 (16.1)
5.0] 130.0 [115.0; 145.0] 0.999
] 70.0 [64.0; 80.0] 0.468
0.026
733 (73.6)
179 (18.0)
33 (3.3)
51(5.1)
4.0 [2.0; 9.0] 0.001ientsristic
(n  4
0; 73.2
24.6)
3; 28.7
20.7)
68.5)
34.1)
54.6)
12.2)
5.4)
; 8.9]
5; 291
; 12.0]
3; 100
43.2)
43.9)
12.9)
.0; 14
0; 80.0
65.8)
23.7)
4.9)
5.6)
; 11.2]
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May 25, 2010:2383–9 No-Reflow and 5-Year Mortalityyocardial perfusion grade (TMPG) 0 or 1, at least 10 min
fter the end of PCI procedure. A TMPG 0 was defined when
ontrast failed to enter the vasculature; TMPG 1, when
ontrast slowly entered but failed to exit the vasculature (16).
cintigraphic study. The 99mTc-sestamibi single-photon
mission computed tomography (SPECT) was performed 7 to
4 days after PCI. Patients received an intravenous injection of
7 mCi (1,000 MBq) of 99mTc-sestamibi, and SPECT was
erformed 6 to 8 h after injection of radioactive agent. A
ultihead camera system, equipped with low energy and high
esolution collimators, was used for myocardial imaging. Im-
ges were acquired in a 64  64 matrix by an acquisition time
f 40 s per image. With dedicated software (ICON version
.0.2, Siemens Medical Systems, Inc., Hoffman Estates, Illi-
ois), transaxial slices were reconstructed. A volumetric sam-
ling tool was applied to create polar maps of relative distri-
ution throughout the entire left ventricle. Each polar map was
ormalized to its individual maximum. The defect size was
efined as the 50% uptake area. All measurements were
erformed in the scintigraphic core laboratory by investigators
naware of clinical or angiographic data.
Angiographic Characteristics in Patients With NTable 2 Angiographic Characteristics in Pat
Characteristic No-Re
Left ventricular ejection fraction, %* 48.
Number of narrowed coronary arteries
1
2
3
Multivessel disease
Lesion location
Left main coronary artery
Left anterior descending coronary artery
Left circumflex coronary artery
Right coronary artery
Venous bypass graft
Vessel size, mm 2.9
Pre-interventional TIMI flow grade
0
1
2
3
Post-interventional TIMI flow grade
0
1
2
3
TIMI myocardial perfusion grade
0
1
2
3
Type of intervention
Stenting
Balloon angioplastyData are median [25th; 75th percentiles] or n (%). *Available in 1,322 patien
TIMI  Thrombolysis In Myocardial Infarction.nd points and follow-up. The primary outcome of this
nalysis was 5-year mortality. The follow-up information
as obtained by a telephone call at 30 days, a visit at 6
onths, a telephone call at 1 year, and annual telephone
alls thereafter. Patients who had cardiac complaints under-
ent a complete clinical, electrocardiographic, and labora-
ory evaluation. Information about death was obtained from
ospital records, death certificates, or telephone contact
ith relatives of the patient or referring physician. The
ollow-up information was obtained by personnel blinded to
he clinical characteristics of the patients.
tatistical analysis. Data are presented as median (with
5th and 75th percentiles) or counts and proportions
percentages). The distribution of the data was analyzed
ith the 1-sample Kolmogorov-Smirnov test. Categorical
ata were compared with the chi-square test. Continuous
ata were compared with the Wilcoxon rank-sum test. Five-
ear mortality was estimated by applying the Kaplan-Meier
ethod and log-rank test, which allowed the calculation of
dds ratios [ORs] (with 95% confidence intervals [CIs] and
espective p values) associated with no-reflow or reflow after
ow and ReflowWith No-Reflow and Reflow
n  410) Reflow (n  996) p Value
; 54.0] 50.0 [43.0; 57.0] 0.001
0.109
1.0) 364 (36.5)
1.5) 303 (30.4)
7.5) 329 (33.1)
9.0) 632 (63.5) 0.046
0.001
.5) 3 (0.3)
2.9) 453 (45.5)
4.4) 177 (17.8)
8.3) 355 (35.6)
.9) 8 (0.8)
; 3.31] 2.89 [2.57; 3.25] 0.325
0.001
8.5) 426 (42.8)
4.9) 101 (10.1)
0.0) 241 (24.2)
.6) 228 (22.9)
0.001
.6) 0 (0.0)
.0) 0 (0.0)
2.4) 0 (0.0)
2.9) 996 (100)
0.001
9.0) 0 (0.0)
6.3) 0 (0.0)
.7) 195 (19.6)
.0) 801 (80.4)
0.514
6.6) 875 (87.9)
3.4) 121 (12.1)o-Reflients
flow (
0 [39.9
127 (3
129 (3
154 (3
283 (6
2 (0
176 (4
59 (1
157 (3
16 (3
2 [2.55
240 (5
61 (1
82 (2
27 (6
23 (5
37 (9
133 (3
217 (5
283 (6
108 (2
19 (4
0 (0
355 (8
55 (1ts.
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No-Reflow and 5-Year Mortality May 25, 2010:2383–9rimary PCI. Univariable and multivariable Cox proportional
azards models were used to assess the association between
o-reflow and mortality. All variables of Tables 1 and 2 plus
o-reflow and infarct size were entered into the univariable
odel with 5-year mortality as the dependent variable; vari-
bles that resulted significant (p 0.05) from univariable Cox
roportional hazards model were entered into the multivariable
ox proportional hazards model using the backward variable
election method. We compared the discriminatory power of
ultivariable models regarding 5-year mortality with and
ithout the variable no-reflow by calculating the integrated
iscrimination improvement, according to Pencina et al. (17).
All analyses were performed using the S-PLUS statistical
ackage (Insightful Corp., Seattle, Washington). A p 
.05 was considered to indicate statistical significance.
esults
he study sample included 1,406 patients with STEMI
ho underwent primary PCI and had infarct size measure-
ent by 99mTc-sestamibi SPECT imaging 7 to 14 days
fter intervention. The group with no-reflow included 410
atients (193 patients with TIMI flow grade 2 and 217
atients with TIMI flow grade 3 and TMPG 2). The
roup with reflow included 996 patients. None of the
atients with TIMI flow grade 2 had a TMPG of 3.
aseline characteristics. Baseline characteristics of the
atients are shown in Table 1. Patients with no-reflow were
f older age, had a higher proportion of patients with prior
oronary artery bypass surgery, and higher values of peak
roponin, peak creatine kinase-myocardial band, and
-reactive protein; and lower values of glomerular filtration
ate compared with patients with reflow. Furthermore,
atients with no-reflow were less often smokers and had a
onger time interval from symptom onset to hospital admis-
ion than patients with reflow. Patients with no-reflow had
tendency for being less often in Killip class I than were
atients with reflow. Angiographic data are shown in Table
. Multivessel disease was more often encountered among
atients with no-reflow than among patients with reflow.
he group with no-reflow had lower left ventricular ejection
raction and higher proportion of patients with baseline
IMI flow grades 0 and 1 compared with patients with
eflow (Table 2). Bare-metal stents were used in 274
atients with no-reflow and in 630 patients with reflow
66.8% vs. 66.3%; p  0.20).
o-reflow and scintigraphic infarct size. In the whole
tudy patients, infarct size median (25th to 75th percentiles)
n the 7 to 14 days SPECT imaging was 10.0% (2.0% to
4.0%) of the left ventricle. The tertiles of infarct size were
s follows: first tertile, 0% to 5.0% of the left ventricle;
econd tertile, 5.0% to 18.1% of the left ventricle; third
ertile 18.1% of the left ventricle. Infarct size in the 7 to
4 days SPECT imaging was 15.0% (6.0% to 29.0%) of the
eft ventricle in patients with no-reflow versus 8.0% (2.0% to 51.0%) of the left ventricle in patients with reflow (p 
.001) (Fig. 1).
o-reflow and 5-year mortality. There were 132 deaths
uring the follow-up: 59 deaths occurred among patients
ith no-reflow and 73 deaths occurred among patients with
eflow (Kaplan-Meier estimates of 5-year mortality 18.2%
nd 9.5%, respectively; OR: 2.02, 95% CI: 1.44 to 2.82; p
.001) (Fig. 2).
Deaths were of cardiovascular origin in 90 patients
68.2%). Of them, 42 deaths occurred in patients with
o-reflow and 48 deaths occurred in patients with reflow
estimates of 5-year mortality 12.4% and 6.3%, respectively;
R: 2.18, 95% CI: 1.46 to 3.27; p  0.001).
o-reflow, infarct size, and 5-year mortality. Five-year
ortality associated with no-reflow was analyzed according
o tertiles of infarct size in the 7 to 14 days SPECT
maging. The data show that with the increase in infarct
ize, the frequency of no-reflow phenomenon increased
ignificantly (p for trend0.001). In each of the infarct size
ertiles, the presence of no-reflow was associated with an
ncreased risk of 5-year mortality (Table 3).
The univariable correlates (p  0.05) of 5-year mortality
ere no-reflow, age, sex, body mass index, diabetes mellitus,
rterial hypertension, previous myocardial infarction, previ-
us coronary artery bypass surgery, anterior infarct location,
illip class, glomerular filtration rate, C-reactive protein,
eft ventricular ejection fraction, multivessel disease, infarct-
elated artery, and scintigraphic infarct size. After applica-
ion of backward variable selection method in the multiva-
iable Cox model, 7 variables (no-reflow, age, diabetes,
illip class, baseline C-reactive protein, multivessel disease,
nd infarct size) remained as independent correlates of
Figure 1 Infarct Size in the 7 to 14 Days
Scintigraphy in Groups With Reflow and No-Reflow
Data are medians with 25th to 75th
and 5th to 95th percentiles. LV  left ventricle.-year mortality (Table 4). The inclusion of the no-reflow
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May 25, 2010:2383–9 No-Reflow and 5-Year Mortalityn the multivariable model was associated with an improved
iscriminatory power of the model regarding the prediction
f the 5-year mortality (absolute integrated discrimination
mprovement  0.0108, relative integrated discrimination
mprovement  7.0%; p  0.028).
iscussion
he present study represents the largest series of patients
ith STEMI treated with primary PCI in whom the
ong-term impact of no-reflow on mortality has been
eported. The no-reflow and infarct size were estimated
sing the angiographic and scintigraphic criteria that are
onsidered as gold standard techniques for diagnosis of
o-reflow (2) and infarct size measurement (18) in the
linical setting. The main findings of this study can be
ummarized as follows: 1) in patients with STEMI, the
evelopment of no-reflow phenomenon after primary PCI
redicts an increased risk of death up to 5 years after the
cute event; and 2) the no-reflow phenomenon provides
rognostic information that is independent of and beyond
hat provided by other relevant clinical factors including the
nfarct size.
Our group has recently examined the impact of no-reflow
n 1-year mortality among patients undergoing PCI for
TEMI (12). The current study significantly expands the
Figure 2 Kaplan-Meier Curves of 5-Year Mortality
Red line  reflow group; blue line  no-reflow group.
CI  confidence interval; HR  hazard ratio.
Frequency of No-Reflow and 5-Year Mortality in PaWith No-Reflow and Reflow in Each Infarct SizTable 3 Frequency of No-R flow and 5-Year MWith No-Reflow and Reflow in Eac
Infarct Size Tertiles No-Reflow No-Reflo
1 (n 452) 83 (18.3) 9 (1
2 (n 474) 146 (30.8) 17 (1
3 (n 480) 181 (37.7) 33 (2
Data are counts, proportions (no-reflow data), or Kaplan-Meier estimat
versus patients with reflow.
CI  confidence interval.ndings of our prior study by the following means: 1) we
sed a more sensitive definition of no-reflow in the current
tudy so that no-reflow comprises nearly 30% (as opposed to
0%) of the study group now; 2) we have extended
ollow-up to true long term (5 years) to assess the impact of
his complication; and 3) unlike the prior study, we are able
o identify the independent importance of no-reflow even
hen controlling for infarct size. Thus, our study confirms
nd extends the findings of our own group as well as those
f other groups with important insight into the prevalence
nd outcomes of this condition, and furthermore, is the first
tudy to suggest that the importance of no-reflow may not
e mechanistically related only to infarct size.
The question whether no-reflow impacts the long-term
rognosis seems particularly relevant considering that no-
eflow is a transient phenomenon that resolves over time in
early 50% of patients (19). Few prior studies with inade-
uate sample sizes have investigated the long-term progno-
is of patients with no-reflow phenomenon after primary
CI (8,9). Morishima et al. (8) studied 120 patients with a
rst acute myocardial infarction treated by PCI and found
hat angiographically defined no-reflow was an independent
redictor of cardiac death over a mean follow-up of 5.8
ears. In a study by Bolognese et al. (9) that included 124
atients with acute myocardial infarction, microvascular
bstruction diagnosed by myocardial contrast echocardiog-
aphy was the only independent predictor of cardiac death
ver a mean follow-up of 46 months. By including 1,400
atients with STEMI treated by primary PCI and by using
he most accurate criteria for the diagnosis of no-reflow, our
stilelity in Patients
arct Size Tertile
ear Mortality
p Reflow Group Odds Ratio (95% CI)*
19 (7.2) 2.01 (0.93–4.38)
21 (8.4) 1.90 (1.02–3.57)
33 (13.4) 1.73 (1.07–2.79)
year mortality. *The risk of 5-year mortality in patients with no-reflow
orrelates of 5-Year Mortality and Hazard Ratiosalculated by Cox Pr por ional s M delTable 4 Correlates of 5-Year Mort lity nd Hazard RatiosCalculated by Cox Proportional Hazards Model
Variable
Adjusted Hazard Ratio
(95% CI) p Value
No-reflow phenomenon 1.66 (1.17–2.36) 0.004
Age, for 10-yr increase 1.75 (1.50–2.05) 0.001
Diabetes mellitus 1.46 (1.01–2.11) 0.040
Killip class, for 1-class increase 1.46 (1.23–1.73) 0.001
Baseline C-reactive protein, for 1-mg/l increase 1.02 (1.01–1.04) 0.012
Multivessel disease, versus single vessel 1.83 (1.14–2.93) 0.013
Infarct size, for 5% of the left ventricle increase* 1.09 (1.05–1.14) 0.001
Measured in the 7 to 14 days single-photon emission computed tomography imaging.
CI  confidence interval.tiente Terorta
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2388 Ndrepepa et al. JACC Vol. 55, No. 21, 2010
No-Reflow and 5-Year Mortality May 25, 2010:2383–9tudy provides the strongest confirmation of the long-term
rognostic impact of no-reflow phenomenon.
Previous studies have convincingly demonstrated a strong
ssociation between no-reflow and infarct size (10–12).
everal clinical studies have shown that infarct size is an
mportant predictor of mortality (13,14). In a recent study,
e have demonstrated that the extent of initial area at risk
n patients with STEMI is an independent correlate of
o-reflow, and that no-reflow per se independently predicts
he infarct size 7 to 14 days after the acute event (12). This
nherent relationship between no-reflow and infarct size
ffers evidence that at least a part of the impact of no-reflow
n the prognosis is mediated through the infarct size.
owever, the present study provides evidence that no-
eflow offers additional prognostic information beyond that
ediated by the infarct size. First, in each of the tertiles of
nfarct size, the presence of no-reflow was associated with an
ncreased risk of long-term mortality. Second, the multiva-
iable analysis showed that no-reflow phenomenon pre-
icted the long-term mortality independent of infarct size
mong other potential confounders. Thus, additional mech-
nisms are needed to explain the strong impact of no-reflow
henomenon on the long-term mortality of patients with
TEMI.
Evidence available suggests that microvascular obstruc-
ion—the morphological basis of the no-reflow phenome-
on—is a major determinant of the subsequent left ventric-
lar remodeling after primary PCI (3,12,20–22). A recent
tudy by Ørn et al. (20) has demonstrated that persistence of
icrovascular obstruction 1 week after an acute event was
ssociated with attenuated infarct healing, increased vol-
mes, and reduced left ventricular function at long-term
ollow-up, possibly reflecting a more severe myocardial
amage. A recent study with magnetic resonance imaging
howed that persistence of microvascular obstruction was a
ore powerful predictor of global and regional functional
ecovery than was transmural extension of infarction (22).
n earlier study by Wu et al. (3) demonstrated that
icrovascular obstruction predicts subsequent ventricular
emodeling (increased left ventricular volumes and wall
hinning at 6 months) and cardiovascular adverse events (a
omposite of death, reinfarction, congestive heart failure or
troke) even after being controlled for infarct size. In
atients with no-reflow after primary PCI, the persistence
f suboptimal blood flow 6 months after acute event was
ssociated with a significant deterioration of the left ven-
ricular function compared with patients who showed res-
lution of the no-reflow in the 6-month angiography (12).
he increased incidence of malignant ventricular arrhyth-
ias, congestive heart failure, and cardiac death among
atients with no-reflow has also been demonstrated (8).
ince left ventricular remodeling is a predictor of long-term
rognosis (23), these findings strongly suggest that no-
eflow may impact prognosis through its impact on subse-
uent ventricular remodeling predisposing for cardiovascu-
ar adverse events and increased mortality.tudy limitations. The present study focused primarily on
he long-term mortality of patients with no-reflow after
rimary PCI. We accept as a limitation that we could not
rovide information on the time-course of no-reflow phe-
omenon and the evolution of TIMI flow grade after
ntervention. Although pharmacological agents were occa-
ionally used to treat no-reflow phenomenon after primary
CI, these agents were not systematically used, and thus
heir therapeutic effects can not be tested in the setting of
resent study. Data on angiographic thrombotic burden in
he infarct-related artery were not available. However,
issing thrombotic burden data do not weaken our main
nalysis of the association between no-reflow and long-term
ortality.
onclusions
he no-reflow phenomenon after primary PCI was a strong
redictor of 5-year mortality in patients with STEMI.
o-reflow after PCI provides prognostic information inde-
endent of and beyond that provided by infarct size. The
ndings of the current study raise the awareness of the harmful
ffects of the no-reflow phenomenon, call attention to better
iagnosis and treatment, and re-emphasize the need for
ontinuation of research to better understand and treat the
o-reflow phenomenon in patients with STEMI after
rimary PCI.
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